New radioactive drug targets Hard-to-Treat gut and adrenal tumors

NCT ID NCT06427798

First seen Oct 31, 2025 · Last updated Apr 24, 2026 · Updated 23 times

Summary

This study tests a new drug that combines a targeting protein with a radioactive particle to kill cancer cells in people with advanced gastrointestinal neuroendocrine tumors or pheochromocytoma/paraganglioma that have already been treated with radiation therapy. The goal is to find the safest dose and see if it shrinks tumors. About 66 adults will receive the drug through an IV over four 8-week cycles and be followed for up to 10 years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PHEOCHROMOCYTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.